ECONOMIC EVALUATION ANALYSIS IN THE TREATMENT OF BIPOLAR DISORDER WITH ARIPIPRAZOLE AND OTHER ATYPICAL ANTIPSYCHOTIC DRUGS IN SPAIN
Author(s)
Ramirez de Arellano A1, Rubio-Terrés C2, Baca E3, Riesgo Y4, Luque J1, Mena E51Bristol-Myers Squibb Iberia, Madrid, Spain, 2HealthValue, Madrid, Spain, 3Hospital Universitario Puerta de Hierro, Madrid, Spain, 4Bristol-Myers Squibb Iberia, Malaga, Spain, 5Otsuka Pharmaceuticals, Barcelona, Spain
OBJECTIVES: This analysis investigates the relative efficiency in the treatment of BD with the use atypical antipsychotics (AA): aripiprazole (ARI); olanzapine (OLA); quetiapine (QUE); risperidone (RIS); and ziprasidone (ZIP). METHODS: our analysis takes into consideration the treatment cost of AA and the impact on hospitalization costs associated with each AA. Mean daily dose of each AA, length of treatment and the probability of hospitalization for each AA were obtained from a retrospective study (90 days of follow-up) in 6,162 BD patients (Jing et al. 2009). The minimum acquisition cost per mg. of the mean daily dose, for each AA, is regarded as an efficiency criterion in Hospital Pharmacy Departments. The cost per day of hospitalization (€347.90) and the length of hospitalization associated to BD (18.1 days; 14.5-21.7) were obtained from a Spanish study. RESULTS: after 90 days of follow-up, hospitalization rates were higher with OLA (8.7%), QUE (8.5%), RIS (8.6%) and ZIP (10.2%) in comparison with ARI (5.9%; 5.8%; 5.7%; 6.5%, respectively). The treatment of BD with ARI gave rise to the following cost savings per patient, in relation to other AA: €149.31 ARI versus OLA; €33.42 ARI versus QUE; €19.45 ARI versus RIS; and €242.22 ARI versus ZIP. A sensitivity analysis tested the following variables: minimum daily dose for each AA; maximum daily dose for each AA; length of treatment with AA; and probability of hospitalization for each AA. The sensitivity analysis confirms the cost savings associated with aripiprazole, with the only exception of risperidone where the cost saving per patient is almost neutral (€-2.89). CONCLUSIONS: using the criterion of cost rationalization based upon the minimum acquisition cost per mg. aripiprazole may have economic benefits over other AA in terms of lower psychiatric treatment costs and lower total health care costs in the Spanish NHS.
Conference/Value in Health Info
2010-11, ISPOR Europe 2010, Prague, Czech Republic
Value in Health, Vol. 13, No. 7 (November 2010)
Code
PMH36
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Mental Health